Ironwood Pharmaceuticals, Inc. (IRWD)
NASDAQ: IRWD · IEX Real-Time Price · USD
7.85
-0.03 (-0.38%)
Apr 30, 2024, 10:35 AM EDT - Market open
Ironwood Pharmaceuticals Revenue
In the year 2023, Ironwood Pharmaceuticals had annual revenue of $442.74M with 7.83% growth. Revenue in the quarter ending December 31, 2023 was $117.55M with 9.66% year-over-year growth.
Revenue (ttm)
$442.74M
Revenue Growth
+7.83%
P/S Ratio
2.80
Revenue / Employee
$1,658,184
Employees
267
Market Cap
1.23B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 442.74M | 32.14M | 7.83% |
Dec 31, 2022 | 410.60M | -3.16M | -0.76% |
Dec 31, 2021 | 413.75M | 24.23M | 6.22% |
Dec 31, 2020 | 389.52M | -38.89M | -9.08% |
Dec 31, 2019 | 428.41M | 81.77M | 23.59% |
Dec 31, 2018 | 346.64M | 48.36M | 16.21% |
Dec 31, 2017 | 298.28M | 24.32M | 8.88% |
Dec 31, 2016 | 273.96M | 124.40M | 83.18% |
Dec 31, 2015 | 149.56M | 73.12M | 95.66% |
Dec 31, 2014 | 76.44M | 53.56M | 234.06% |
Dec 31, 2013 | 22.88M | -127.36M | -84.77% |
Dec 31, 2012 | 150.25M | 84.37M | 128.09% |
Dec 31, 2011 | 65.87M | 22.01M | 50.19% |
Dec 31, 2010 | 43.86M | 9.54M | 27.78% |
Dec 31, 2009 | 34.32M | 15.94M | 86.70% |
Dec 31, 2008 | 18.38M | 7.92M | 75.68% |
Dec 31, 2007 | 10.46M | 7.32M | 233.25% |
Dec 31, 2006 | 3.14M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Omnicell | 1.15B |
Collegium Pharmaceutical | 566.77M |
Mirum Pharmaceuticals | 186.37M |
Xencor | 168.34M |
4D Molecular Therapeutics | 20.72M |
Spyre Therapeutics | 886.00K |
IRWD News
- 4 days ago - Ironwood Pharmaceuticals to Host First Quarter 2024 Investor Update Call - Business Wire
- 21 days ago - ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Ironwood Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm - Accesswire
- 25 days ago - INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Ironwood Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm - Accesswire
- 4 weeks ago - Ironwood Pharmaceuticals Announces Positive Results from its Phase II Exploratory STARGAZE Trial of Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease (SR GI aGVHD) - Business Wire
- 5 weeks ago - IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Ironwood Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm - Accesswire
- 5 weeks ago - INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Ironwood Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm - Accesswire
- 6 weeks ago - SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Ironwood Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm - Accesswire
- 7 weeks ago - Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In March - Ironwood Pharmaceuticals (NASDAQ:IRWD), Integra Lifesciences (NASDAQ:IART) - Benzinga